Janus Henderson Group PLC Oncorus, Inc. Transaction History

Janus Henderson Group PLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$5.03 - $11.63 $407,580 - $942,378	-81,030 Closed	0 $0
Q3 2021 Nov 16, 2021	SELL	$9.29 - $14.27 $1.97 Million - $3.02 Million	-211,797 Reduced 72.33%	81,030 $758,000
Q2 2021 Aug 16, 2021	BUY	$13.3 - $17.3 $627,307 - $815,971	47,166 Added 19.2%	292,827 $4.03 Million
Q1 2021 May 17, 2021	BUY	$11.89 - $35.55 $2.06 Million - $6.15 Million	173,089 Added 238.51%	245,661 $3.41 Million
Q4 2020 Feb 16, 2021	BUY	$15.0 - $35.15 $1.09 Million - $2.55 Million	72,572 New	72,572 $2.34 Million

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

Stay updated on Janus Henderson Group PLC with notifications on news.